← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Regenerative Research Foundation
Rensselaer, NY
$46,044,831
Total funding
27
Grants
Funding over time
peak $6.4M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,265,652 · 25
DOD$2,779,179 · 2
By mechanism
R01$17,288,703 · 9
U01$9,543,635 · 2
R35$5,000,540 · 1
RF1$4,129,930 · 3
—$2,779,179 · 2
UH3$2,549,156 · 1
Investigators at Regenerative Research Foundation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
ASSESSMENT OF SELECTIVE INHIBITORS OF NUCLEAR EXPORT (SINE) FOLLOWING SPINAL CORD INJURY.$2,104,968
· FY2019 · Defense Health Agency
Cell Type and Regional Vulnerability in Frontotemporal Dementia$2,094,351
RF1 · FY2021 · NS
Human iPSC model of Cerebro-Vascular Interactions in ADRD$1,931,965
R61 · FY2024 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,658,307
U01 · FY2021 · AG
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,635,911
U01 · FY2022 · AG
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,603,401
U01 · FY2023 · AG
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,573,956
U01 · FY2024 · AG
iPSC-based Model to Study Frontotemporal Dementia Due to MAPT Mutation$1,540,579
RF1 · FY2025 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,514,673
U01 · FY2025 · AG
Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human$682,000
R35 · FY2023 · NS
MODELING NF2 TUMORS FOR DRUG SCREENING USING INDUCED PLURIPOTENT STEM CELLS$674,211
· FY2015 · Department of Defense
Cell Type and Regional Vulnerability in Frontotemporal Dementia$663,462
R01 · FY2025 · NS
Cell Type and Regional Vulnerability in Frontotemporal Dementia$663,462
R01 · FY2024 · NS
Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human$661,540
R35 · FY2024 · NS
Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration$645,471
R01 · FY2021 · EY
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2023 · EY
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2021 · EY
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$638,369
UH3 · FY2022 · EY
Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration$634,049
UH3 · FY2024 · EY
Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human$595,000
R35 · FY2020 · NS